Eagle Pharmaceuticals Shareholders Still Have Time to Participate in the EGRX Class Action; Contact Robbins LLP Today
29 déc. 2023 08h00 HE
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue